HOXD8 Antibody, HRP conjugated

Mechanistic Studies in Cancer Biology

HOXD8 antibodies, including HRP-conjugated variants, are widely used to investigate HOXD8's dual role in cancer progression:

• Tumor Suppression: In breast cancer, HOXD8 overexpression inhibits proliferation, migration, and invasion by downregulating ILP2 (Inhibitor of Apoptosis-Like Protein-2) . WB analyses using HOXD8 antibodies confirmed reduced ILP2 and MMP2/9 levels in HOXD8-overexpressing cells .

• Chemoresistance: In ovarian cancer, elevated HOXD8 expression correlates with cisplatin resistance. Studies using HOXD8 antibodies demonstrated increased HOXD8 protein levels in cisplatin-resistant cell lines (SKOV3-DDP and HO-8910PM) .

Bladder Cancer Progression

HOXD8 promotes bladder cancer (BCa) by stabilizing oncogenic lncRNA LINC01116. Knockdown experiments with HOXD8 antibodies revealed reduced BCa cell proliferation, migration, and epithelial-mesenchymal transition (EMT) .

Recommended Workflow

1. Sample Preparation: Use RIPA buffer for protein extraction from cells/tissues .

2. Western Blotting:

   • Dilution: Optimize between 1:200–1:1000 .

   • Blocking: 5% skimmed milk or BSA .

   • Detection: Chemiluminescent substrates (e.g., ECL) for HRP signal visualization .

Validation Data

• Positive Controls: Reactivity confirmed in human ovarian and gastric cancer tissues .

• Specificity: Recognizes HOXD8 in human, mouse, and rat samples .

Comparative Analysis of HOXD8 Antibodies

Key Research Findings

• Breast Cancer: HOXD8 binds the ILP2 promoter, suppressing tumorigenesis .

• Ovarian Cancer: HOXD8 overexpression enhances cisplatin resistance by reducing apoptosis .

• Bladder Cancer: HOXD8 stabilizes LINC01116 lncRNA via DKC1 interaction, driving EMT .